Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Non-Current Liabilities (2016 - 2025)

Spyre Therapeutics' Total Non-Current Liabilities history spans 11 years, with the latest figure at $35.9 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 33.66% year-over-year to $35.9 million; the TTM value through Dec 2025 reached $35.9 million, down 33.66%, while the annual FY2025 figure was $35.9 million, 33.66% down from the prior year.
  • Total Non-Current Liabilities reached $35.9 million in Q4 2025 per SYRE's latest filing, down from $46.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $89.2 million in Q2 2023 to a low of $20.8 million in Q4 2022.
  • Average Total Non-Current Liabilities over 5 years is $41.4 million, with a median of $35.9 million recorded in 2025.
  • Peak YoY movement for Total Non-Current Liabilities: surged 295.53% in 2023, then plummeted 75.2% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $26.0 million in 2021, then dropped by 19.75% to $20.8 million in 2022, then surged by 53.45% to $32.0 million in 2023, then soared by 69.05% to $54.1 million in 2024, then crashed by 33.66% to $35.9 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Total Non-Current Liabilities are $35.9 million (Q4 2025), $46.3 million (Q3 2025), and $83.1 million (Q2 2025).